<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) exceeds <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> as the leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In the USA alone, approximately a million individuals suffer an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e>) annually </plain></SENT>
<SENT sid="2" pm="."><plain>As the prevalence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors (e.g. <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) rises, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> is increasing in younger individuals </plain></SENT>
<SENT sid="3" pm="."><plain>Fortunately, existing therapies have improved post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> mortality, but in turn have increased the prevalence of post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HF) </plain></SENT>
<SENT sid="4" pm="."><plain>Approximately half-a-million new HF cases are diagnosed each year in the USA </plain></SENT>
<SENT sid="5" pm="."><plain>In the next 25 years, up to 15% of the population over the age of 65 in the USA is projected to have HF </plain></SENT>
<SENT sid="6" pm="."><plain>Therapeutic interventions that prevent/reverse <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, prevent post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> HF and halt the progressive functional deterioration once HF occurs are <z:hpo ids='HP_0000001'>all</z:hpo> needed </plain></SENT>
<SENT sid="7" pm="."><plain>Cell therapy - either via exogenous delivery or by endogenous mobilization of cells - may be able to do so, in part, by improving the body's capacity for repair </plain></SENT>
<SENT sid="8" pm="."><plain>To date, primarily bone marrow- or blood-derived cells have been utilized after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMI</z:e> to prevent left ventricular dysfunction, and skeletal myoblasts have been transplanted into failing myocardium </plain></SENT>
<SENT sid="9" pm="."><plain>Preclinical studies are directed at prevention/reversal of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> with bone marrow precursors, and ultimately at replacing failing heart with a cell-based bioartificial construct </plain></SENT>
</text></document>